Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 64 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Semaglutide for treating peripheral arterial disease (PAD) and type 2 diabetes	Semaglutide (Ozempic)	Peripheral arterial disease (PAD) , Type 2 diabetes	Cardiovascular System , Endocrine Nutritional and Metabolic Disorders	2022	View \| Download
Semaglutide for treating overweight or obesity with cardiovascular disease	Semaglutide (Ozempic)	Cardiovascular disease (CVD) , Obesity	Cardiovascular System , Endocrine Nutritional and Metabolic Disorders	2023	View \| Download
Semaglutide for treating obesity-related heart failure	Semaglutide (Ozempic)	Obesity-related heart failure	Cardiovascular System , Endocrine Nutritional and Metabolic Disorders	2022	View \| Download
Sacubitril/valsartan for the treatment of post-acute myocardial infarction patients with left ventricular systolic dysfucntion and/or pulmonary congestion – first line	Entresto; LCZ 696 (fixed dose combination: Sacubitril; Valsartan)	Post-acute myocardial infarction (MI)	Cardiovascular System	2021	View \| Download
Sacubitril-valsartan for previously untreated chronic heart failure with reduced ejection fraction in children	Sacubitril-valsartan	Chronic heart failure	Cardiovascular System	2022	View \| Download
Rivaroxaban for reducing the risk of major thrombotic vascular events in symptomatic peripheral arterial disease patients with a recent lower extremity revascularisation procedure	Rivaroxaban (Xarelto; BAY 59-7939)	Peripheral arterial disease (PAD)	Cardiovascular System	2019	View \| Download
Rivaroxaban for prevention of cardiovascular events following an episode of decompensated heart failure	Rivaroxaban (Xarelto; BAY 59-7939)	Heart failure (HF)	Cardiovascular System	2018	View \| Download
Rivaroxaban (Xarelto) in Combination with Aspirin for Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease	Rivaroxaban (Xarelto; BAY 59-7939)	Cardiovascular disease (CVD)	Cardiovascular System	2017	View \| Download
Rituximab (MabThera) maintenance therapy for granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)	Rituximab (MabThera; Rituxan; RG 105)	Granulomatosis with polyangiitis (GPA) , Microscopic polyangiitis (MPA)	Cardiovascular System	2017	View \| Download
Rexmyelocel-T for critical limb ischaemia in patients with diabetes mellitus	REX-001 (Rexmyelocel-T)	Critical limb ischaemia (CLI)	Cardiovascular System	2017	View \| Download